Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

Summary

This purpose of this study is to assess the safety of ramelteon, once daily (QD), in subjects with chronic obstructive pulmonary disease.

Timeline

Start

2003-08

Primary completion

2004-03

Completion

2004-03

Publications

• Background Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath. 2008 Aug;12(3):243-50. doi: 10.1007/s11325-007-0156-4.

Drugs

Indications